Bcl-xL expression increased with the progression of pancreatic neoplasia from pancreatic intraepithelial neoplasia (PanIN)-1 to pancreatic ductal adenocarcinoma. Bcl-xL overexpression in low-grade PanINs inhibits oncogene-induced senescence, whereas it inhibits apoptosis in high-grade PanINs, accelerating carcinogenesis. Bcl-xL deficiency increased senescence in PanINs.
BACKGROUND & AIMS:
Bcl-xL, an anti-apoptotic Bcl-2 family protein, is overexpressed in 90% of pancreatic ductal adenocarcinoma (PDAC) cases. However, Bcl-xL expression in pancreatic intraepithelial neoplasias (PanINs) and its significance in PDAC carcinogenesis remain unclear. The aim of this study was to elucidate the significance of Bcl-xL expression in PanINs.
METHODS:
We investigated the expression levels of Bcl-xL in pancreas-specific KrasG12D (P-KrasG12D) mice and human PanINs and PDAC. We examined the impact of Bcl-xL expression on Kras-mutated pancreatic neoplasia using Bcl-xL-overexpressing P-KrasG12D mice and Bcl-xL-knockout P-KrasG12D mice.
RESULTS:
In P-KrasG12D mice, the number of PanINs increased and their grades progressed with age. In total, 55.6% of these mice developed PDAC at 12-14 months. According to the immunohistochemistry of mouse pancreas and human resected specimens, Bcl-xL expression was increased significantly in PanIN-1 compared with that in normal pancreatic ducts, and augmented further with the progression of pancreatic neoplasia in PanIN-2/3 and PDAC. Oncogene-induced senescence was observed frequently in PanIN-1, but rarely was detected in PanIN-2/3 and PDAC. Bcl-xL overexpression significantly accelerated the progression to high-grade PanINs and PDAC and reduced the survival of P-KrasG12D mice. Bcl-xL overexpression in P-KrasG12D mice suppressed oncogeneinduced senescence in PanIN-1 and inhibited apoptosis in PanIN-3. Bcl-xL deficiency in P-KrasG12D mice induced cellular senescence in PanIN-2/3.
CONCLUSIONS:
Bcl-xL expression increases with the progression from PanIN-1 to PDAC, whereas oncogene-induced senescence decreases. Bcl-xL overexpression increases PDAC incidence rates by inhibiting oncogene-induced senescence and apoptosis in PanINs. Conversely, Bcl-xL deficiency induced senescence in PanINs. Anti-Bcl-xL treatments may have the P ancreatic ductal adenocarcinoma (PDAC) is one of the most highly aggressive forms of human cancer, with <5% of patients surviving after 5 years, and the early detection of PDAC remains difficult. 1, 2 The number of patients with PDAC has increased steadily, and PDAC has increased to the fourth leading cause of cancer-related death in the United States. 3 Pancreatic intraepithelial neoplasias (PanINs) are the most frequent and well-characterized precursor lesions of PDAC. 4, 5 PanINs are classified into PanIN-1, 2, and 3, depending on the degree of cytologic and architectural atypia. 6 Kras mutations, the most frequent genetic alteration of PDAC, are identified in more than 90% of low-grade PanIN-1/2, as well as high-grade PanIN-3 and PDAC in human beings. 7, 8 A pancreas-specific Kras mutant mouse model, which develops PanINs and PDAC over time, 9 is suitable for studying both PanINs and PDAC.
Bcl-xL is one of the anti-apoptotic Bcl-2 family proteins. 10 Bcl-xL inhibits Bak or Bax activation, which is an essential event for apoptosis execution. 11, 12 Previous reports have clarified that increased Bcl-xL expression is observed in 90% of PDAC cases based on immunohistochemical analysis using tumor tissues of PDAC patients.
PanIN-1 to PDAC. Bcl-xL overexpression accelerated PDAC carcinogenesis with the decrease of senescence in PanIN-1 and apoptosis in PanIN-3, reducing survival in Kras mutant mice. Conversely, Bcl-xL deficiency induced senescence in PanINs. This study showed the function of Bcl-xL and its effect on the process of pancreatic carcinogenesis.
Materials and Methods

Genetically Engineered Mouse Models and Mouse Strains
The Pdx1-Cre transgenic (Tg) strain on a C57BL/6/FVB background and the LSL-KrasG12D knock-in strain on a C57BL/6/129 background were obtained from the Mouse Models of Human Cancer Consortium (National Cancer Institute-Frederick, Bethesda, Maryland). The LSLKrasG12D allele is expressed at endogenous levels after Cre-mediated excision of a transcriptional stopper element. 9, 15 A heterozygous hemagglutinin-hBcl-xL transgenic strain expressing the human Bcl-xL gene under the regulation of the CAG promoter on a C57BL/6/129 background (Bcl-xL Tg mice) using a hemagglutinin-tagged human Bcl-xL expression plasmid (pcDNA3HAbcl-xL) was described previously. 16 Mice carrying a bcl-x gene with 2 loxP sequences in the promotor region and a second intron (bcl-x flox/flox mice) were described previously. 17 These strains were intercrossed to produce the experimental cohorts. Mice were genotyped by polymerase chain reaction analysis (primer sequences are provided in the Supplementary Materials and Methods section). All mice were maintained with free access to food and water in a specific pathogen-free facility. They were treated with humane care under approval from the Animal Care and Use Committee of Osaka University Medical School.
Histologic Evaluation
Formalin-fixed, paraffin-embedded mouse pancreas tissues were sectioned (4 mm) and stained with H&E. PanIN lesions and carcinoma were classified according to histopathologic criteria. 18 To quantify the progression of PanIN lesions, the number and their grades from each sample were obtained from 10 high-power (Â200) microscopic fields. The area of normal-appearing pancreatic tissue was measured using the Hybrid Cell Count analysis of a digital microscope image (BZ-X700; Keyence, Osaka, Japan). Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining, which is used to detect apoptotic cells, 19, 20 was performed as previously described. 21 
Immunohistochemistry
The sections of mouse pancreas were processed further for immunohistochemistry (IHC). The sections were immersed in 1Â Target Retrieval Solution (pH 6.0) (Dako, Glostrup, Denmark) for Bcl-xL and p21 staining. The samples were heated to 120 C in a decloaking chamber for antigen retrieval. The endogenous peroxidase activity was quenched by incubating with 3% hydrogen peroxide in methanol for 30 minutes. After sections were blocked in 5% goat serum for 1 hour, they were incubated with antibodies against Bcl-xL (1:200, #2764; Cell Signaling Technology, Danvers, MA) and p21 (1:400, sc-471; Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4 C. After rinsing with phosphate-buffered saline, the slides were incubated with secondary antibody (SignalStain Boost IHC detection reagent; Cell Signaling Technology) for 30 minutes. After washes with phosphate-buffered saline, the sections were incubated with 3,3'-diaminobenzidine for 30 seconds and counterstained with hematoxylin. In every staining set, negative controls were applied by omission of the primary antibody.
Evaluation of the Immunohistochemistry Results
Immunohistochemical staining for Bcl-xL was defined as a detectable immunoreaction in the cytoplasm. The number of positive cells was estimated semiquantitatively. The quantity of the immunostaining was evaluated as follows: 0 corresponded to no positive immunostaining, 1 corresponded to less than 20%, 2 corresponded to 20%-75%, and 3 corresponded to more than 75% positive cells. 22 The intensity of the immunostaining was evaluated as follows: 0 corresponded to no staining, 1 corresponded to weak staining, 2 corresponded to moderate staining, and 3 corresponded to intense staining. 23 A combined total score for the immunostaining was calculated by adding both the quantitative score and the intensity score. The total score for each sample was the average score obtained from 10 high-power (magnification, Â200) microscopic fields.
Senescence-Associated b-Galactosidase Assay
To assess senescence in vivo, mouse pancreatic cryosections were stained for senescence-associated b-galactosidase (SA-b-gal) activity according to a previously described procedure. 24 Briefly, the frozen pancreas sections were fixed in 0.2% glutaraldehyde with 2% formaldehyde for 1 minute and incubated overnight in SA-b-gal solution from the Senescence b-Galactosidase Staining Kit (Cell Signaling Technology) at 37 C. This staining kit also was used for the evaluation of senescence in vitro according to the manufacturer's protocol. A total of approximately 500 cells was counted in 4 randomly selected fields to determine the percentage of senescent cells.
Human Samples
Formalin-fixed, paraffin-embedded samples were obtained from 9 patients with PDAC accompanied by PanIN lesions and 7 patients with other types of pancreatic tumors (neuroendocrine tumor, 2; serous cystic neoplasm, 2; solid pseudopapillary neoplasm, 1; epithelial cyst, 1; and hamartoma, 1) who underwent pancreas resection without preoperative therapy between March 2009 and March 2012. The use of resected samples was approved by the Institutional Review Board for Clinical Research at Osaka University Hospital (14435). Written informed consent was obtained from each patient. These samples were sectioned (4 mm) and stained with H&E. The sections also were stained for Bcl-xL immunohistochemistry. The slides were treated by immersion in 1Â Target Retrieval Solution (pH 6.0) (Dako) and heated to 120 C in a decloaking chamber. They were incubated with 3% hydrogen peroxide in methanol for 15 minutes to quench the endogenous peroxidase activity. After blocking with 5% goat serum for 1 hour, they were incubated with anti-Bcl-xL antibody (1:200, 2764; Cell Signaling Technology) overnight at 4 C. After the incubation with secondary antibody (SignalStain Boost IHC detection reagent; Cell Signaling Technology) for 30 minutes, the sections were developed with 3,3'-diaminobenzidine for 2 minutes and counterstained with hematoxylin. Negative controls were performed by omitting the primary antibody. The total score for each sample was the average score obtained from 6 high-power (magnification, Â200) microscopic fields.
Cell Lines and Culture Conditions
The human pancreatic cancer cell lines PANC-1 and MIA PaCa-2 were purchased from the American Type Culture Collection (Manassas, VA). These cells were cultured in Dulbecco's modified Eagle medium containing 10% heatinactivated fetal bovine serum and antibiotic-antimycotic (Thermo Fisher Scientific, Rockford, IL) in a 5% CO 2 atmosphere at 37 C. PANC-1 and MIA PaCa-2 cells were transfected with Bcl-xL small interfering RNAs (siRNAs) (s1920-22; Thermo Fisher Scientific) using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific) according to the manufacturer's protocol.
Apoptosis Assay and Cell Viability
Cells were assayed for apoptosis by monitoring caspase-3/7 activity using the Caspase-Glo assay (Promega, Madison, WI) according to a previously described procedure. 25 Cell viability was evaluated by the water-soluble tetrazolium salt (WST) assay with cell count reagent SF (Nacalai Tesque, Kyoto, Japan).
Western Blot Analysis
The Western blot analysis was performed using a previously described method. 26 The following antibodies were used: anti-Bcl-xL antibody, anti-Bcl-2 antibody, anti-Mcl-1 antibody (Cell Signaling Technology), anti-p21 antibody (Santa Cruz Biotechnology), and anti-b-actin antibody (Sigma-Aldrich, St. Louis, MO).
Statistical Analysis
Survival curves were plotted using the Kaplan-Meier method and compared by the log-rank test using Statistics Package for Social Science software version 21.0 (SPSS, Inc, Chicago, IL). The data were presented as the means ± SD or medians and interquartile range, with comparisons using the Student t test or the Mann-Whitney U test, respectively. The incidences of PDAC were compared using the Fisher exact test. P values less than .05 were considered statistically significant.
All authors had access to the study data and reviewed and approved the final manuscript.
Results
Bcl-xL Expression Increases in Both PanINs and PDAC
To analyze Bcl-xL expression levels in PanINs and PDAC, pancreas sections were examined in pancreas-specific Krasmutated mice (Pdx1-Cre LSL-KrasG12D mice [P-KrasG12D mice]). Control littermates of Pdx1-Cre mice did not show any histologic changes in the pancreas from 2 to 14 months ( Figure 1A and B) . In contrast, P-KrasG12D mice showed sporadic PanIN-1 lesions at 2 months. The number of PanINs and their grade gradually progressed at 4 months and increased further at 7 months ( Figure 1A and C) . At 12-14 months, widespread low-to high-grade PanINs were detected in all mice, and invasive ductal adenocarcinomas developed in 5 of 9 mice (55.6%) ( Figure 1A ). The percentage of normal-appearing areas in pancreas sections significantly decreased with age ( Figure 1B ). Immunohistochemistry showed Bcl-xL overexpression in the cytoplasm of PDACs from P-KrasG12D mice, consistent with previous reports of resected specimens from human beings 13, 14 ( Figure 1D and E). Of importance, Bcl-xL was overexpressed significantly, even in PanIN-1. Bcl-xL overexpression was augmented in PanIN-2/3 and enhanced further in PDAC ( Figure 1D and E). As shown in Western blot analysis, Bcl-xL expression levels were increased in the pancreas of P-KrasG12D mice compared with those in control littermates at 4 months, and gradually increased with age ( Figure 1F ). We also examined other anti-apoptotic Bcl-2 family proteins, including Mcl-1 and Bcl-2. 27 Mcl-1 expression levels were increased slightly in P-KrasG12D mice, whereas Bcl-2 expression levels did not increase ( Figure 1F ).
Next, we evaluated Bcl-xL expression levels in PanINs using clinical resected samples. Consistent with the murine results, Bcl-xL also was overexpressed in the cytoplasm of human PanINs and PDAC samples (Figure 2 ). Total immunostaining scores were increased significantly in human PanIN-1 compared with those in normal human pancreatic ducts, and were increased further with the progression to human PanIN-2/3 and human PDAC (Figure 2) . Collectively, Bcl-xL was overexpressed in early stage PanINs and increased with the progression of pancreatic neoplasia.
Bcl-xL Overexpression in Kras-Mutated Cells Promotes PDAC Carcinogenesis
Next, we examined the impact of Bcl-xL overexpression on the development of PanINs and PDAC. For this purpose, we generated Bcl-xL Tg P-KrasG12D mice by mating P-KrasG12D mice and Bcl-xL Tg mice. We confirmed that Bcl-xL expression levels in the pancreas were increased remarkably in Bcl-xL Tg mice compared with those in control wild-type littermates ( Figure 3A) . In physiological settings, Bcl-xL Tg mice did not show histologic abnormalities of the pancreas ( Figure 3B ) or any significant differences in pancreas/body weight ratios or serum levels of amylase and lipase compared with littermate wild-type mice ( Figure 3C ). To examine the impact of Bcl-xL overexpression on carcinogenesis, we compared Bcl-xL Tg P-KrasG12D mice with their P-KrasG12D littermates. Up-regulation of Bcl-xL in the pancreas of Bcl-xL Tg P-KrasG12D mice compared with P-KrasG12D mice was confirmed by Western blot analysis ( Figure 4A ). Stronger Bcl-xL expression was observed in the cytoplasm of PanINs and PDAC from Bcl-xL Tg P-KrasG12D mice than in that from P-KrasG12D mice, as assessed by immunohistochemistry ( Figure  4B ). P-KrasG12D mice had no macroscopic or microscopic PDAC at 2, 4, or 7 months (Figure 4C-E) . In contrast, 41.7% (5 of Figure 2 . Bcl-xL expression levels are increased in human PanINs and PDAC. Human resected pancreatic tissues of 9 patients with PDAC accompanied by PanIN lesions and 7 patients with other types of pancreatic tumors were stained with H&E and anti-Bcl-xL antibody. Given that the pancreatic tissues of 9 patients with PDAC contained many PanINs in the nontumor area, normal pancreatic ducts were evaluated using nontumor areas of pancreatic tissues from 7 patients with other types of pancreatic tumors. (A) Representative images of H&E and Bcl-xL immunohistochemistry staining of pancreas sections. Scale bar: 100 mm (original magnification, Â200); width of insets: 100 mm. (B) Total score for the immunostaining of Bcl-xL. *P < .05.
12) of Bcl-xL Tg P-KrasG12D mice developed microscopic PDAC at 2 months, and 8.3% (1 of 12) developed macroscopically visible PDAC ( Figure 4D and E) . At 4 and 7 months, all had developed macroscopically evident PDAC ( Figure 4C-E) . H&E staining showed that the area of the normal-appearing pancreas of Bcl-xL Tg P-KrasG12D mice was significantly smaller than that of P-KrasG12D mice ( Figure 4F) , and the number of PanIN-2/3 lesions in the pancreas of Bcl-xL Tg P-KrasG12D mice at 2 months was significantly larger than that of P-KrasG12D mice at 2 months ( Figure 4G ). All Bcl-xL Tg P-KrasG12D mice died within 1 year; their median survival was 7.8 months ( Figure 4H ), which was significantly shorter than their P-KrasG12D littermates. These data suggest that Bcl-xL overexpression accelerates carcinogenesis of Kras-mutated pancreatic neoplasia, reducing survival in P-KrasG12D mice.
Bcl-xL Overexpression Suppresses Oncogene-Induced Senescence in Low-Grade PanINs and Apoptosis in High-Grade PanINs
To address the mechanisms by which Bcl-xL overexpression promotes PDAC carcinogenesis, we examined the effect of apoptosis in PanIN lesions and PDAC. We compared P-KrasG12D mice at 12-14 months with Bcl-xL Tg P-KrasG12D mice at 2 months because both had low-grade PanINs as well as high-grade PanINs and PDAC. The percentage of TUNEL-positive cells was 0.44% ± 0.19% in PanIN-1, 0.66% ± 0.69% in PanIN-2, and 1.21% ± 0.50% in PanIN-3 of P-KrasG12D mice ( Figure 5A and B) . The frequency of TUNEL-positive cells in PanIN-1 and PanIN-2 did not decrease significantly with Bcl-xL overexpression, whereas the number of TUNEL-positive cells decreased significantly in PanIN-3 ( Figure 5A and B). These data suggest that Bcl-xL overexpression might not have an effect on apoptosis in low-grade PanIN lesions. In contrast, Bcl-xL overexpression suppressed apoptosis in high-grade PanIN-3.
Next, we further examined another mechanism of acceleration of carcinogenesis in Bcl-xL Tg P-KrasG12D mice. We examined senescence in P-KrasG12D mice and Bcl-xL Tg P-KrasG12D mice using SA-b-gal activity, which is a specific detector of senescence. 28 In 12-to 14-month P-KrasG12D mice, SA-b-gal-positive cells were observed frequently in PanIN-1, but were decreased remarkably in PanIN-2/3 and PDAC ( Figure 5C ). In contrast, few positive cells were detected in the PanIN-1, PanIN-2/3, and PDAC lesions from Bcl-xL Tg P-KrasG12D mice at 2 months ( Figure 5C ). Immunostaining for p21, another marker associated with oncogene-induced senescence, 29 also showed that the number of p21-positive cells in PanIN-1 lesions was reduced significantly in Bcl-xL Tg P-KrasG12D mice at 2 months compared with that in P-KrasG12D mice at 12-14 months ( Figure 5D and 5E). There were few p21-positive PanIN-2/3 and PDAC cells in both mice ( Figure 5D and E). These data suggest that oncogene-induced senescence is induced in PanIN-1 of P-KrasG12D mice and that it is inhibited by the increase in Bcl-xL expression levels.
Bcl-xL Deficiency in Kras-Mutated Cells Increases the Number of Senescent Cells in High-Grade PanINs
Next, we examined the impact of Bcl-xL deficiency on the induction of senescence in PanINs. Pancreas-specific Bcl-xL knockout mice without the Kras mutation (bcl-x flox/flox Pdx1-Cre mice) did not show any phenotype under physiological conditions ( Figure 6 ). We generated pancreasspecific Kras-mutated and Bcl-xL knockout mice (Bcl-xL knockout [KO] P-KrasG12D mice) by mating P-KrasG12D mice and bcl-x flox/flox mice ( Figure 7A and B) . SA-b-galpositive cells were observed frequently in PanIN-1 lesions from both Bcl-xL KO P-KrasG12D mice and P-KrasG12D mice. Positive cells also were detected in PanIN-2/3 lesions from Bcl-xL KO P-KrasG12D mice, but rarely were observed in PanIN-2/3 lesions from P-KrasG12D mice ( Figure 7C ). According to the immunostaining for p21, the percentage of p21-positive cells in PanIN-2/3 lesions was significantly higher in Bcl-xL KO P-KrasG12D mice than in P-KrasG12D mice, but a significant difference was not detected in the PanIN-1 lesions from these mice ( Figure 7D and E) . The frequency of TUNEL-positive cells in PanIN lesions of any grade did not increase significantly with Bcl-xL deficiency in P-KrasG12D mice ( Figure 7F and G) . A lower percentage of Bcl-xL KO P-KrasG12D mice developed PDAC at 12 months than littermate P-KrasG12D mice (35.7% [5 of 14] vs 83.3% [5 of 6] ), although the difference did not reach statistical significance (P ¼ .07). These results suggest that Bcl-xL inhibition increases the number of senescent cells in highgrade PanINs, which might suppress the progression from PanINs to PDAC.
Bcl-xL Inhibition Induces Oncogene-Induced Senescence and Apoptosis in PDAC
Finally, to examine the possibility of apoptotic induction and oncogene-induced senescence by Bcl-xL inhibition in PDAC, PANC-1 and MIA PaCa-2 cells were treated with siRNAs against Bcl-xL. siRNA-mediated knockdown of Bcl-xL led to a significant increase in caspase-3/7 activity and a significant decrease in cell viability ( Figure 8A ). Bcl-xL knockdown increased p21 expression levels, as evaluated by Western blot analysis ( Figure 8B ). Bcl-xL knockdown also significantly increased the number of b-galactosidasepositive cells ( Figure 8C ). Collectively, these data suggest that Bcl-xL inhibition efficiently induces oncogene-induced senescence and apoptosis in PDAC.
Discussion
Bcl-xL overexpression has been observed in several types of cancer 30, 31 and is associated with tumor growth, malignant biological behaviors, and survival. [32] [33] [34] According to previous studies of PDAC, Bcl-xL up-regulation is observed frequently in human samples 13, 14, 35 and is associated with a poorer prognosis, 23 but the effect of Bcl-xL overexpression during PDAC carcinogenesis and whether Bcl-xL expression is observed in precancerous PanIN lesions has not been investigated completely. As shown in this study, Bcl-xL expression was increased significantly in the cytoplasm of PanIN-1 lesions compared with that in normal pancreatic ducts, and was augmented gradually with the progression of pancreatic neoplasia in Kras mutant mouse models and human samples ( Figures 1D-F and 2A and B) . We report that Bcl-xL expression increases in PanINs as well as PDAC. A-F, Â40; G-I, Â200) . (E) The ratio of microscopic and macroscopic PDAC *P < .05. (F) The percentage of normal pancreas at 2 months (n ¼ 12 per each), 4 months (n ¼ 10 or 11), and 7 months (n ¼ 6 per each). *P < .05. (G) The number of PanINs per defined area in the pancreas sections of P-KrasG12D mice and Bcl-xL Tg P-KrasG12D mice (n ¼ 12 per group) at 2 months *P < .05. (H) Kaplan-Meier survival analysis of P-KrasG12D (n ¼ 11) and Bcl-xL Tg P-KrasG12D mice (n ¼ 12). *P < .05.
As clearly shown in the present study, Bcl-xL overexpression led to the acceleration of carcinogenesis in Krasmutated pancreatic neoplasia. All Bcl-xL Tg P-KrasG12D mice developed grossly evident PDAC at as early as 4 months, whereas P-KrasG12D mice showed only microscopic PanIN lesions ( Figure 4C-E) . Genetically engineered mouse models of PDAC are based commonly on Kras mutations, 9 and various mutations or deletions of genes, such as p53, 36 Ink4a, 15 and transforming growth factor-b, 37 result in rapid carcinogenesis of Kras-mutated pancreatic neoplasia. However, no murine PDAC models have been reported to harbor gene mutations or deletions in Bcl-2 family proteins. This study showed accelerated pancreatic carcinogenesis using a mouse model of Bcl-2 family proteins. The results showing that 41.7% (5 of 12) of Bcl-xL Tg P-KrasG12D mice developed microscopic PDAC at as early as 2 months ( Figure 4D and E) and the number of microscopic PanIN-2/3 lesions was increased significantly compared with that in P-KrasG12D mice ( Figure 4G ) suggest that Bcl-xL up-regulation in the presence of Kras mutation causes the rapid progression of low-grade PanINs to highgrade PanINs and PDAC, reducing the survival of Bcl-xL Tg P-KrasG12D mice ( Figure 4H ). The overexpression of anti-apoptotic proteins, including Bcl-xL, in tumor cells directly accelerates tumor proliferation by inhibiting apoptosis. 32, 38 Together with the in vitro findings that siRNA-mediated Bcl-xL knockdown in Kras-mutated PDAC cells decreased cell viability and increased apoptosis ( Figure 8A ), accelerated tumor cell proliferation caused by Bcl-xL overexpression, also may contribute to the reduced survival. Bcl-xL staining recently was detected in the nucleus and cytoplasm of PDAC. 35 As reported by Choi et al, 39 nuclear Bcl-xL promotes the epithelial-mesenchymal transition, migration, invasion, and stemness of cell lines derived from pancreatic neuroendocrine tumors and breast cancer.
In the present study, we observed Bcl-xL immunostaining in the cytoplasm of PanINs and PDAC, consistent with previous immunohistochemical studies of PDAC, 23,40 but we did not detect immunopositivity in the nucleus (Figures 1D, 2A , and 4B). However, there remains a possibility that nuclear Bcl-xL, which may be expressed in undetectable levels by immunohistochemistry, affects the development of PDAC in Bcl-xL Tg P-KrasG12D mice.
In the present study, we addressed 2 possible mechanisms by which Bcl-xL overexpression accelerated the progression to high-grade PanINs and PDAC in Kras mutant mice: inhibition of apoptosis and inhibition of oncogene-induced senescence. Bcl-xL is an anti-apoptotic protein, 27 and its overexpression is expected to inhibit PanIN apoptosis, resulting in the acceleration of carcinogenesis. A small number of apoptotic cells was observed in PanIN-1 lesions from PKrasG12D mice ( Figure 5A and B), consistent with a previous report of resected samples from human beings. 41 Bcl-xL overexpression in Kras-mutated neoplasia did not significantly decrease the number of apoptotic cells in PanIN-1 lesions ( Figure 5A and B) . In contrast, the number of apoptotic cells was suppressed significantly by Bcl-xL overexpression in PanIN-3 ( Figure 5A and 5B). Kras mutation induces oncogene-induced senescence, 42 which is regarded as a tumor-suppressive effect because the suppression of senescence leads to the rapid progression to high-grade PanINs and PDAC. 43, 44 In the present study, oncogene-induced senescent cells were observed frequently in PanIN-1 lesions from PKrasG12D mice, but not in PanIN-2/3 and PDAC lesions ( Figure 5C-E) . Importantly, Bcl-xL overexpression strongly suppressed the oncogene-induced senescence observed in the PanIN-1 lesions from P-KrasG12D mice ( Figure 5C-E) . These data suggest that the suppressive effect of Bcl-xL overexpression on oncogene-induced senescence shows a greater impact on low-grade PanINs than high-grade PanINs. As shown by Yosef et al, 45 joint inhibition of Bcl-w and Bcl-xL, but not single inhibition of Bcl-xL, eliminates senescent fibroblasts by inducing apoptosis. In the present study, Bcl-xL overexpression decreased the number of senescent cells in PanIN-1 lesions from P-KrasG12D mice without inducing apoptosis ( Figure 5 ). Although Yosef et al 45 described the effect of Bcl-xL on apoptosis in senescent cells, we reported the effect of Bcl-xL on the regulation of senescence in PanINs. Collectively, Bcl-xL overexpression in PanINs promotes progression to PDAC by inhibiting apoptosis, particularly in high-grade PanINs, and oncogene-induced senescence in lowgrade PanINs.
In the experiments using Bcl-xL KO P-KrasG12D mice, Bcl-xL deficiency significantly increased the number of senescent cells in PanIN-2/3 lesions from the P-KrasG12D mice ( Figure 7C-E) . In P-KrasG12D mice, Bcl-xL expression showed a graded increase with the progression from PanIN-1 to PDAC, whereas oncogene-induced senescence was detected frequently in PanIN-1, but rarely found in PanIN-2/3 and PDAC ( Figures 1D and E , and 5C-E). Bcl-xL overexpression in PanIN-1 lesions significantly decreased the number of senescent cells ( Figure 5C-E) . These results suggest that the gradual increase of Bcl-xL expression suppresses senescence in PanINs. Regarding cancer cell senescence, previous studies have shown that Bcl-xL overexpression inhibits senescence by preventing reactive oxygen species generation. 46 ABT-737, a small molecule that inhibits Bcl-xL, increases senescence and reactive oxygen species levels. 47 In the present study, Bcl-xL knockdown in PDAC cell lines increased the number of senescent cells ( Figure 8C ). Collectively, Bcl-xL inhibition could induce senescence in PDAC as well as PanINs. Advanced PDAC remains difficult to treat, 48 and therapies preventing the progression of PanINs to PDAC could be promising treatments to reduce the incidence of PDAC. Treatments for Bcl-xL may be an efficient preventive therapy for patients at high risk of developing PanINs, such as patients with chronic pancreatitis. 49 In conclusion, we clarified that Bcl-xL expression levels increase with the progression of pancreatic neoplasia from PanIN-1 to PDAC, whereas oncogene-induced senescence decreases. Bcl-xL overexpression suppresses oncogeneinduced senescence in low-grade PanINs and inhibits apoptosis in high-grade PanINs, promoting the progression to high-grade PanINs and PDAC. Together with the finding that Bcl-xL deficiency in Kras mutant mice increases senescence, Bcl-xL is suggested to be an effective target for the prevention of PDAC by inducing senescence in PanINs.
